TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27605392

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAM (active metabolite of Ticagrelor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRS2211 (P2Y13 antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIM (inactive metabolite of Ticagrelor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticagrelor (in PLATO trial)
Number of subjects: 0
Study: 24091567

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis
Number of subjects: 10344

Group type: EXPERIMENTAL
Intervention: Weighted risk index
Number of subjects: 10344

Group type: EXPERIMENTAL
Intervention: Overall surgical population
Number of subjects: 10344
Study: 24360173

Group type: EXPERIMENTAL
Intervention: Narrow gastric tube (NGT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Whole stomach (WS)
Number of subjects: 104
Study: 20966417

Group type: EXPERIMENTAL
Intervention: CHA₂DS₂‐VASc scheme
Number of subjects: 7329

Group type: COMPARATOR
Intervention: NICE 2006
Number of subjects: 7329

Group type: COMPARATOR
Intervention: Other contemporary RSS
Number of subjects: 7329

Group type: EXPERIMENTAL
Intervention: CHA₂DS₂‐VASc score
Number of subjects: 7329

Group type: EXPERIMENTAL
Intervention: Age 75 years or older
Number of subjects: 7329

Group type: EXPERIMENTAL
Intervention: Coronary artery disease
Number of subjects: 7329

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 7329

Group type: EXPERIMENTAL
Intervention: Reported alcohol use
Number of subjects: 7329
Study: 19058662

Group type: EXPERIMENTAL
Intervention: T-shirt odors rated by women
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Facial photographs rated by women
Number of subjects: 44
Study: 16791444

Group type: EXPERIMENTAL
Intervention: Standard balanced anesthesia in morbidly obese patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard balanced anesthesia in nonobese patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall hemodynamic measurements during surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Episodes of hemodynamic instability
Number of subjects: 60
Study: 12442345

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 or 10 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 24
Study: 9989712

Group type: EXPERIMENTAL
Intervention: Hirudin (0.4 mg/kg bolus then 0.15 mg kg(‐1) h(‐1) infusion; n=5083)
Number of subjects: 10141

Group type: COMPARATOR
Intervention: Heparin (5000 units bolus then 15 units kg(‐1) h(‐1); n=5058)
Number of subjects: 10141

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 10141

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 10141
Study: 8524697

Group type: EXPERIMENTAL
Intervention: Gallopamil (G)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Metoprolol (M)
Number of subjects: 26
Study: 2156976

Group type: EXPERIMENTAL
Intervention: Veterans Administration (VA) Medical Center
Number of subjects: 45

Group type: COMPARATOR
Intervention: Private hospital
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Environmental Rating Scale
Number of subjects: 45
Study: 6933739

Group type: EXPERIMENTAL
Intervention: Progestasert
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copper-T-200
Number of subjects: 0
Study: 31715077

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily (n = 30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31216327

Group type: EXPERIMENTAL
Intervention: QbTest report (computer task measuring attention, impulsivity and activity)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No QbTest report
Number of subjects: 250
Study: 27899371

Group type: EXPERIMENTAL
Intervention: Topography-guided crosslinking (PiXL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Uniform 9 mm crosslinking (CXL)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 37
Study: 25929531

Group type: EXPERIMENTAL
Intervention: Movement System Impairment (MSI)-based classification treatment
Number of subjects: 148

Group type: COMPARATOR
Intervention: General exercise program (stretching and strengthening exercises)
Number of subjects: 148
Study: 23709314

Group type: EXPERIMENTAL
Intervention: Therapeutic Assessment (TA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Assessment As Usual (AAU)
Number of subjects: 69
Study: 21233774

Group type: EXPERIMENTAL
Intervention: Fluid Restriction (FR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fluid Intake (FI)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rehydration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: TearLab osmolarity system
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Urine Specific Gravity (USG)
Number of subjects: 14
Study: 19179203

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: perindopril/indapamide
Number of subjects: 375
Study: 17251530

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 600

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 600
Study: 14732637

Group type: EXPERIMENTAL
Intervention: Deep-plane face-lift
Number of subjects: 40

Group type: COMPARATOR
Intervention: SMAS plication face-lift
Number of subjects: 40
Study: 11757831

Group type: EXPERIMENTAL
Intervention: Nasal mupirocin ointment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral rifampin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rifampin or mupirocin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral rifampin prophylaxis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nasal or exit-site mupirocin
Number of subjects: 14
Study: 9299803

Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8401551

Group type: EXPERIMENTAL
Intervention: High calorie preload
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report rating scales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stroop task
Number of subjects: 0
Study: 3717693

Group type: EXPERIMENTAL
Intervention: Transfusion of 1 unit of blood @ 5 ml/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transfusion of 2 units of blood @ 10 ml/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transfusion of 2 units of blood @ 5 ml/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transfusion of 1 unit of blood @ 10 ml/min
Number of subjects: 40
Study: 31188229

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.1%
Number of subjects: 68

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 68
Study: 28918703

Group type: EXPERIMENTAL
Intervention: RPH+sMMH
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: RPH alone
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Other treatments (MMH, PPH, PPH+sMMH)
Number of subjects: 3000
Study: 25963295

Group type: EXPERIMENTAL
Intervention: Electroacupuncture with Neiguan (PC6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture with Zhongwan (CV12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture with both PC6 and CV12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antiemetic only (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (all groups)
Number of subjects: 0
Study: 23231499

Group type: EXPERIMENTAL
Intervention: 800 μg of misoprostol orally
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 21796123

Group type: EXPERIMENTAL
Intervention: Combination therapy (standard-dose candesartan 8 mg/day + controlled-release nifedipine 20 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Up-titrated monotherapy (candesartan 12 mg/day)
Number of subjects: 86
Study: 19182483

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 16981108

Group type: EXPERIMENTAL
Intervention: Dextrose 50 %
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study: 15342168

Group type: EXPERIMENTAL
Intervention: Revascularisation within 30 days
Number of subjects: 7800

Group type: COMPARATOR
Intervention: Medically treated patients
Number of subjects: 7800
Study: 11025708

Group type: EXPERIMENTAL
Intervention: Bicalutamide monotherapy (150 mg daily)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Castration (orchiectomy or 3.6 mg goserelin acetate every 28 days)
Number of subjects: 480
Study: 9195140

Group type: EXPERIMENTAL
Intervention: Perceptual assessment and treatment provided in a stroke unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional wards (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual impairment assessment using Rey figure copy
Number of subjects: 0
Study: 8257455

Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 3086203

Group type: COMPARATOR
Intervention: Vasopressin alone (0.66 units per min)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vasopressin plus sublingual nitroglycerin (0.6 mg every 30 min for 6 hr)
Number of subjects: 39
Study: 3296856

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 92
Study: 31381021

Group type: EXPERIMENTAL
Intervention: 1 febrile UTI
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 2 febrile UTIs
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 3 or more febrile UTIs
Number of subjects: 345
Study: 28560853

Group type: EXPERIMENTAL
Intervention: Combination therapy (gefitinib combined with pemetrexed and carboplatin)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed plus carboplatin)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 121
Study: 25041275

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.33, 0.34, 0.38 U/kg)
Number of subjects: 62
Study: 23877013

Group type: EXPERIMENTAL
Intervention: Timing of cytotoxic treatment (≤ 28 days)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Timing of cytotoxic treatment (> 28 days)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Postoperative residual disease (n=70)
Number of subjects: 191

Group type: COMPARATOR
Intervention: No postoperative residual disease (n=121)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Extent of surgery
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Preoperative performance status
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Perioperative complications
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: FIGO stage
Number of subjects: 191
Study: 21300516

Group type: EXPERIMENTAL
Intervention: Empowerment group (active-learning, empowerment approach)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Traditional diabetes education arm (didactic group session)
Number of subjects: 84
Study: 18073007

Group type: EXPERIMENTAL
Intervention: Senofilcon A contact lenses (ACUVUE OASYS Brand Contact Lenses with HYDRACLEAR Plus)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Habitual contact lenses
Number of subjects: 11

Group type: COMPARATOR
Intervention: No contact lenses
Number of subjects: 11
Study: 16858181

Group type: EXPERIMENTAL
Intervention: Anterior approach technique (AA group, n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional approach technique (CA group, n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Anterior approach technique (AA group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional approach technique (CA group)
Number of subjects: 120
Study: 12853996

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) at 60 W
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) at 50 W
Number of subjects: 42

Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 42
Study: 11205449

Group type: EXPERIMENTAL
Intervention: Papaverine (5 mg/ml)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Total pathological skin reactivity to vasomotor agents
Number of subjects: 116
Study: 9260089

Group type: EXPERIMENTAL
Intervention: Voluntary pelvic floor muscle contraction with Conmax
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vaginal electrical stimulation with Conmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Voluntary pelvic floor muscle contraction with Medicon MS 105
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vaginal electrical stimulation with Medicon MS 105
Number of subjects: 12
Study: 8469323

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) 3,600 mg/d
Number of subjects: 111

Group type: COMPARATOR
Intervention: Valproate (VPA) 15 mg/kg/d
Number of subjects: 111
Study: 3486877

Group type: EXPERIMENTAL
Intervention: 25 micrograms 24,25‐dihydroxyvitamin D3
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31431654

Group type: EXPERIMENTAL
Intervention: Higher Family Resource Scale scores at 18 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poor social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Least resources and social support
Number of subjects: 0
Study: 27603763

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive rehabilitation (CR)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Therapist-directed manualized CR
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Integrated therapist-directed CR with cognitive-behavioral psychotherapy (CBT)
Number of subjects: 126
Study: 26866767

Group type: EXPERIMENTAL
Intervention: Transtheoretical model (TTM) behavior change constructs
Number of subjects: 1050
Study: 22422082

Group type: EXPERIMENTAL
Intervention: Ozone nano-bubble water (NBW3) irrigation as an adjunct to mechanical debridement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Full-mouth mechanical debridement with tap water (WATER)
Number of subjects: 22
Study: 22806257

Group type: EXPERIMENTAL
Intervention: Behavioral intervention targeting fruit and vegetable consumption, red meat consumption, multivitamin intake, and physical activity
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: High workplace social capital
Number of subjects: 850
Study: 19939247

Group type: EXPERIMENTAL
Intervention: Standardized patient
Number of subjects: 5

Group type: COMPARATOR
Intervention: Mannequin
Number of subjects: 5
Study: 17710973

Group type: EXPERIMENTAL
Intervention: Hib‐TT Hiberix mixed with GPO's DTPw vaccine (group 1)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Hib‐TT mixed with GPO's DTPw vaccine (group 2)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Hib‐TT mixed with GSK's DTPw vaccine (Tritanrix; group 3)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 360
Study: 15359983

Group type: EXPERIMENTAL
Intervention: Clearance after cimetidine administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Estimated creatinine clearance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard creatinine clearance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inulin clearance
Number of subjects: 40
Study: 12119060

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs) - omeprazole, rabeprazole, pantoprazole, or lansoprazole
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs) - newer PPIs (rabeprazole, pantoprazole, lansoprazole)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Histamine 2-receptor antagonist (ranitidine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9796073

Group type: EXPERIMENTAL
Intervention: Local finger cooling at temperatures of 30 degrees C, 20 degrees C, 15 degrees C, and 10 degrees C
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Local finger cooling
Number of subjects: 136
Study: 8570369

Group type: EXPERIMENTAL
Intervention: Subject-controlled performance feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50% relative performance feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Summary performance feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yoked control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving no performance feedback
Number of subjects: 0
Study: 2403952

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily in the morning
Number of subjects: 248

Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily at night
Number of subjects: 248
Study: 114055

Group type: EXPERIMENTAL
Intervention: Montanoa tomentosa extracts (Zoapatle) administered orally at a daily dose of 1.0 to 1.4 gm-equivalent of dry leaves per kilogram of body weight for two days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Commercial tea (control group) administered orally at the same volume and schedule as Zoapatle extracts
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Montanoa tomentosa extracts (Zoapatle)
Number of subjects: 6
Study: 31415092

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dry needling (DN) of the piriformis muscle, 3 sessions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 32
Study: 28836340

Group type: EXPERIMENTAL
Intervention: Electronic alert system (e-alert) with Geneva Risk Score calculation tool
Number of subjects: 1593

Group type: COMPARATOR
Intervention: Control group (no alert issued)
Number of subjects: 1593

Group type: EXPERIMENTAL
Intervention: Alert group with no score calculation or inconsistent score result
Number of subjects: 1593
Study: 26180051

Group type: COMPARATOR
Intervention: Fish oil supplementation, dosage not specified, duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bacterial lipopolysaccharide (LPS) administration, details not specified.
Number of subjects: 0
Study: 23382157

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 4380

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TS) prophylaxis
Number of subjects: 4380

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 4380
Study: 21368000

Group type: EXPERIMENTAL
Intervention: Motor learning through grasping a robotic arm and guiding a cursor to visual targets for 10 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive experience of limb trajectories matched to those of subjects who actively performed motor learning
Number of subjects: 0
Study: 19407947

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (Zhao's Weitiao No. 3, 40 mL twice a day for 30 days, 6 cycles)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Chemotherapy (OLF protocol: L-OHP+LV+5-FU for 4-6 cycles)
Number of subjects: 163
Study: 18162018

Group type: COMPARATOR
Intervention: Ziprasidone 10-20 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Olanzapine 10 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Aripiprazole 9.75 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 9
Study: 15313741

Group type: EXPERIMENTAL
Intervention: 13-hour curriculum in which residents practiced teaching and received feedback during 1-hour small-group sessions taught twice monthly for 6 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (untrained residents)
Number of subjects: 62
Study: 11207174

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (50 mg/kg once daily) for 10 days
Number of subjects: 220

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (50 mg/kg once daily) for 3 days
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 220
Study: 10198505

Group type: EXPERIMENTAL
Intervention: Structured assessments by practice nurses after a one-day training course
Number of subjects: 0

Group type: COMPARATOR
Intervention: General practitioners (GPs)
Number of subjects: 0
Study: 7851102

Group type: EXPERIMENTAL
Intervention: Rural patients
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Substance abusing patients in rural areas
Number of subjects: 609

Group type: COMPARATOR
Intervention: Urban patients
Number of subjects: 609
Study: 3379230

Group type: EXPERIMENTAL
Intervention: Double-blind shrimp-food challenge
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Open challenge of 16 whole cooked shrimp
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo challenges
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Shrimp prick skin test
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serum shrimp RAST percent
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Composite of positive shrimp prick skin test and elevated serum shrimp-specific IgE
Number of subjects: 30
Study: 29793715

Group type: EXPERIMENTAL
Intervention: Mock interview session
Number of subjects: 59
Study: 28163248

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 200
Study: 25204437

Group type: EXPERIMENTAL
Intervention: Electrostimulation of the K1 acupoint combined with antiemetic tropisetron
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo point electrostimulation combined with antiemetic tropisetron
Number of subjects: 103
Study: 23239683

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (3 g daily for 60 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 21
Study: 21679476

Group type: COMPARATOR
Intervention: Intervention group (girls)
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Control group (girls)
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Intervention group (boys)
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Control group (boys)
Number of subjects: 1465
Study: 18227852

Group type: EXPERIMENTAL
Intervention: Effective electrical stimulation group (ESG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo-controlled group (PG)
Number of subjects: 10